Myriad Genetics's total assets for Q3 2024 were $1.08B, a decrease of -0.35% from the previous quarter. MYGN total liabilities were $349.60M for the fiscal quarter, a 1.45% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.